Global Blood Therapeutics (NASDAQ:GBT) Earns Neutral Rating From Cantor Fitzgerald
Global Blood Therapeutics (NASDAQ:GBT) Earns Neutral Rating From Cantor Fitzgerald
Cantor Fitzgerald reissued their neutral rating on shares of Global Blood Therapeutics (NASDAQ:GBT – Get Rating) in a research note issued to investors on Wednesday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Global Blood Therapeutics' FY2022 earnings at ($4.55) EPS and FY2023 earnings at ($3.03) EPS.
坎特·菲茨杰拉德重新發布了對股份的中立評級 全球血液治療 (NASDAQ: GBT — 獲得評分) 在周三早上向投資者發布的一份研究報告中，Pricetargets.com 報告。坎特·菲茨杰拉德還發布了全球血液治療的 FY2022 盈利（4.55 美元）每股盈利和 FY2023 盈利（3.03 美元）的估計值。
GBT has been the subject of several other research reports. SVB Leerink cut Global Blood Therapeutics from an outperform rating to a market perform rating and set a $68.50 price target for the company. in a report on Tuesday, August 9th. Stifel Nicolaus reaffirmed a hold rating on shares of Global Blood Therapeutics in a report on Monday, August 8th. William Blair cut Global Blood Therapeutics from an outperform rating to a market perform rating in a report on Monday, August 8th. Canaccord Genuity Group raised Global Blood Therapeutics from a hold rating to a buy rating and increased their price target for the company from $40.00 to $72.00 in a report on Monday, August 8th. Finally, Wedbush cut Global Blood Therapeutics to a neutral rating in a report on Monday, August 15th. Twelve analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of $65.50.
GBT 一直是其他幾個研究報告的主題。SVB Leerink 將全球血液治療從「跑贏大市」評級降至市場表現評級，並為該公司設定了 68.50 美元的價格目標。在 8 月 9 日（星期二）的報告中。斯蒂菲爾·尼古拉斯（Stifel Nicolaus）在 8 月 8 日（星期一）的一份報告中重申了全球血液治療學股份的持有評級。威廉·布萊爾（William Blair）在 8 月 8 日星期一的報告中將全球血液治療從「表現超越」評級降至市場。Cannaccord Genuity 集團將全球血液治療從持有評級提高到買入評級，並在 8 月 8 日（星期一）的一份報告中將該公司的目標價格從 $40.00 提高到 72.00 美元。最後，在 8 月 15 日星期一的報告中，Wedbush 將全球血液治療降至中性評級。十二位分析師對該股票進行了持有評級，五名分析師將買入評級分配給該公司。根據 MarketBeat 的數據，該股目前的平均評級為「保持」，共識目標價格為 65.50 美元。
Global Blood Therapeutics Stock Performance
全球血液治療股票表現
NASDAQ GBT opened at $67.99 on Wednesday. The company has a market cap of $4.59 billion, a PE ratio of -13.57 and a beta of 0.46. The stock's 50 day simple moving average is $58.27 and its 200-day simple moving average is $40.00. Global Blood Therapeutics has a 1-year low of $21.65 and a 1-year high of $73.02. The company has a debt-to-equity ratio of 4.92, a current ratio of 6.88 and a quick ratio of 6.17.
納斯達克 GBT 週三開市為 67.99 美元。該公司的市值為 459 億美元，私募股權比率為 -13.57，測試版為 0.46。該股票的 50 天簡單移動平均線為 58.27 美元，其 200 天的簡單移動平均線為 40.00 美元。全球血液治療有一年低點 21.65 美元和 1 年高點 73.02 美元。該公司的債務與權益比率為 4.92，流動比率為 6.88，快速比率為 6.17。
Insider Activity
內幕活動
In other news, insider Nazila Habibizad sold 4,678 shares of Global Blood Therapeutics stock in a transaction on Thursday, August 18th. The stock was sold at an average price of $67.19, for a total value of $314,314.82. Following the completion of the sale, the insider now directly owns 8,918 shares of the company's stock, valued at $599,200.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 4.90% of the company's stock.
在其他消息中，內幕納茲拉·哈比比扎德（Nazila Habibizad）在 8 月 18 日（星期四）的一項交易中出售了 4,678 股全球血液治療股票。該股票以 67.19 美元的平均價格出售，總價值為 314,314.82 美元。出售完成後，內幕人士現在直接擁有該公司股票的 8,918 股，價值為 599,200.42 美元。該銷售在與證券交易委員會的法律文件中披露，該文件可在以下位置獲得 這個鏈接。業內人士擁有公司股票的 4.90%。
Institutional Investors Weigh In On Global Blood Therapeutics
機構投資者權衡全球血液治療
Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC grew its stake in shares of Global Blood Therapeutics by 75.6% in the first quarter. Nisa Investment Advisors LLC now owns 1,510 shares of the company's stock valued at $52,000 after buying an additional 650 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Global Blood Therapeutics in the first quarter valued at $448,000. Candriam Luxembourg S.C.A. boosted its holdings in Global Blood Therapeutics by 16.7% in the first quarter. Candriam Luxembourg S.C.A. now owns 756,708 shares of the company's stock valued at $26,211,000 after purchasing an additional 108,369 shares during the period. Fairmount Funds Management LLC boosted its holdings in Global Blood Therapeutics by 59.1% in the first quarter. Fairmount Funds Management LLC now owns 1,182,307 shares of the company's stock valued at $40,955,000 after purchasing an additional 439,307 shares during the period. Finally, Vestmark Advisory Solutions Inc. boosted its holdings in Global Blood Therapeutics by 44.3% in the first quarter. Vestmark Advisory Solutions Inc. now owns 12,669 shares of the company's stock valued at $439,000 after purchasing an additional 3,892 shares during the period.
機構投資者最近修改了對該公司的持有量。Nisa 投資顧問有限責任公司在第一季度增加了 75.6％ 的全球血液治療學股份的股份。Nisa 投資顧問有限責任公司現在擁有該公司 1,510 股價值為 52,000 美元的股票，在上一個季度額外購買 650 股票後。坎貝爾 ＆CO 投資顧問有限責任公司在第一季度購買了全球血液治療學的新職位，價值為 448,000 美元。坎德里亞姆盧森堡 S.C.A. 在第一季度將其在全球血液治療領域的持有量提高了 16.7％。康德瑞姆盧森堡股份有限公司現在擁有該公司 756,708 股股份，價值 26,211,000 美元，於期內另外購買 108,369 股股份後。Fairmount 基金管理有限責任公司在第一季度將其在全球血液治療領域的持有量提高了 59.1％。費爾蒙基金管理有限責任公司現在擁有該公司股票的 1,182,307 股股份，價值為 40,955,000 美元，在此期間額外購買 439,307 股。最後，Vestmark 諮詢解決方案公司在第一季度將其在全球血液治療領域的持有量提高了 44.3％。維斯特馬克諮詢解決方案公司現在擁有該公司股票的 12,669 股，價值為 439,000 美元，在此期間額外購買 3,892 股後。
About Global Blood Therapeutics
關於全球血液治療
(Get Rating)
(取得評分)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Plood Theraptics, Inc. 是一家生物製藥公司，致力於為鐮狀細胞病（SCD）服務不足的患者群體的發現，開發和提供治療。該公司提供 Oxbryta 片劑，這是一種口服的 SCD 每日一次治療。它還評估了 SCD 青少年和兒科患者的 II 期單劑和多劑 Oxbryta 的安全性和藥代動力學。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- MarketBeat: Week in Review 9/19 – 9/23
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
- 2 Semiconductor Stocks To Watch For Reversals
- 獲取有關全球血液治療研究報告的免費副本
- 市場節拍：評論中的一周 9/19 — 9 月 23 日
- 為什麼特斯拉股票保持彈性？
- 群眾罷工會從增加 EPS 指南中獲得提升嗎？
- 小型股科技的裁員是房屋股票的最佳選手嗎？
- 2 個半導體股票需要注意反轉
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收全球血液治療日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關全球血液治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。